REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Designated Organic Active Ingredient Containing (doai) > Cyclopentanohydrophenanthrene Ring System Doai > Plural Compounds Containing Cyclopentanohydrophenanthrene Ring Systems Plural Compounds Containing Cyclopentanohydrophenanthrene Ring SystemsPlural Compounds Containing Cyclopentanohydrophenanthrene Ring Systems patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.02/01/07 - 20070027124 - Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors and an amount of a sex steroid precursor selected from the group consisting of dehydroepiandrosterone, dehydroepiandrosterone sulfate, androst-5-ene-3β,17β-diol and compounds converted in vivo to one of the foregoing precursor. Further administration of bisphosphonates in combination with selective estrogen receptor modulators and/or sex steroid precursor is disclosed for the medical treatment ... 02/01/07 - 20070027123 - Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors and an amount of a sex steroid precursor selected from the group consisting of dehydroepiandrosterone, dehydroepiandrosterone sulfate, androst-5-ene-3β,17β-diol and compounds converted in vivo to one of the foregoing precursor. Further administration of bisphosphonates in combination with selective estrogen receptor modulators and/or sex steroid precursor is disclosed for the medical treatment ... 02/01/07 - 20070027122 - Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors and an amount of a sex steroid precursor selected from the group consisting of dehydroepiandrosterone, dehydroepiandrosterone sulfate, androst-5-ene-3β,17β-diol and compounds converted in vivo to one of the foregoing precursor. Further administration of bisphosphonates in combination with selective estrogen receptor modulators and/or sex steroid precursor is disclosed for the medical treatment ... 02/01/07 - 20070027121 - Method of treatment of diarrhea-predominant ibs in a female subject receiving contraceptive therapy A method of treatment of symptoms associated with diarrhea-predominant IBS and nonconstipated IBS in a female subject receiving contraceptive therapy, which comprises administering a physiologically effective amount of cilansetron or a pharmaceutically acceptable derivative thereof. ... 01/25/07 - 20070021396 - Oral contraception with trimegestone The invention relates to a method for contraception comprising the administration of trimegestone to a woman of child-bearing age on at least 21 successive days, beginning on day 1 of the menstrual cycle, wherein on at least one of the at least 21 successive days the daily dose of trimegestone ... 01/04/07 - 20070004690 - Quadraphasis continuous graduated estrogen contraceptive A quadraphasic estrogenic/progestogenic contraceptive regimen that provides for a low level of estrogen in the initial phase and in the fourth phase is disclosed. Also described is a contraceptive kit that may be used to practice the method of the invention. ... 12/21/06 - 20060287285 - Methods and compositions for the treatment of pain and other hormone-allergy-related symptoms using dilute hormone solutions A method and composition for the treatment of hormone allergy is disclosed. The method relates to using progesterone dilutions, or any other steroid hormone, to treat the systemic symptoms of hormone allergy, including pain. The composition of the hormone dilutions ranges from 10−1 to 10−5. The hormone dilution may be ... 12/14/06 - 20060281721 - Hrt formulations HRT formulations containing low amounts of estradiol and NETA are prepared. ... 11/30/06 - 20060270642 - Method and apparatus for transdermal or transmucosal application of testosterone Methods, formulations, and devices for providing transdermal or transmucosal delivery of active agents to subjects in need thereof. The formulations and methods treat symptoms of hormonal disorders including hypogonadism, female sexual desire disorder, female menopausal disorder, and adrenal insufficiency. ... 11/09/06 - 20060252734 - Methods of female sexual enhancement A method of sexual enhancement in women includes the steps of identifying a woman requesting sexual enhancement, assuring that the woman's blood includes estradiol within a first predetermined range and testosterone within a second predetermined range, and thereafter administrating a drug selected from the group consisting of vardenafil hydrochloride and ... 10/26/06 - 20060241092 - Contraceptive regimens for lower-weight women The present invention discloses methods of providing contraception to a female based on the body weight of the female. According to the methods provided, the body weight of the female is determined and a contraceptive regimen is selected based on the female's body weight. The selected contraceptive regimen is then ... 10/26/06 - 20060241091 - Extended estrogen dosing contraceptive regimen A method of contraception that provides for sequentially administering to a female of child bearing age: (a) a first composition containing a progestin in an amount equivalent to about 0.3 to about 1.5 mg norethindrone acetate and an estrogen in an amount equivalent to about 5 to about 20 mcg ... 10/19/06 - 20060234990 - Compositions of boswellic acids derived from boswellia serrata gum resin, for treating lymphoproliferative and autoimmune conditions A method of treatment of lymphoproliferative and autoimmune disorders with a new composition of four boswellic acids including β-boswellic acid, 3-O-acetyl-β-boswellic acid, 11-keto-β-boswellic acid, and 3-O-acetyl-11-keto-β-boswellic acid. Boswellic acids of invention have been obtained in a novel industrial process from the gum resin of Boswellia serrata tree, providing standardized composition ... 09/21/06 - 20060211663 - Low dose estrogen interrupted hormone replacement therapy A hormone replacement therapy, comprising a plurality of daily doses of a pharmaceutical preparation, the doses being administered continuously and consecutively in alternating phases of three daily doses, a relatively dominant estrogenic activity phase comprising three daily doses of a substance exhibiting estrogenic activity equivalent to about 1 mg per ... 09/21/06 - 20060211662 - Combination therapy for topical application in the treatment of age-related macular degeneration and ocular hypertension A topical drug composition for the treatment of age-related maculopathy, age-rlated macular degeneration, ocular hypertension, glaucoma or other eye disease resulting from increased intraocular pressure comprising a solution of anabolic androgenic agent and 17-β-estradiol suspended or dissolved in a suitable ophthalmic vehicle is disclosed. In the preferred embodiment, 17-β-estradiol, or ... 09/14/06 - 20060205701 - Solid peroral contraceptive preparations The solid peroral contraceptive contains an effective ingredient combination of dienogest in a daily dosage of equal to or less than 2.0 mg and ethinyl estradiol in a daily dosage of less than 0.03 mg together with one or more pharmaceutically acceptable carriers. The dienogest is released in two stages, ... 08/17/06 - 20060183725 - Pharmaceutical preparation for oral contraception The pharmaceutical preparation for oral contraception has 28 daily dosage units, of which at least 21 daily dosage units each contain from 1.5 mg to 2 mg of dienogest and from 0.015 mg to 0.02 mg of ethinyl estradiol together in a pharmaceutically acceptable carrier. Seven or fewer daily dosage ... 08/17/06 - 20060183724 - Compositions of unconjugated estrogens and methods for their use The present invention relates to compositions containing unconjugated estrogens and methods of their use in the treatment of conditions associated with hypoestrogenism or reduced estrogen levels in females. ... 07/13/06 - 20060154907 - Method of treating hormonal deficiencies in women undergoing estrogen replacement therapy The present invention combines the administration of estrogens with the administration of non-aromatizing androgens to treat hormonal deficiencies in women undergoing estrogen replacement therapy. ... 06/29/06 - 20060142257 - Male contraceptive formulation comprising norethisterone A formulation for male contraception comprising a progestin possessing both estrogenic and androgenic properties is remarkably effective for spermatogenesis suppression in males. The progestin Norethisterone (NET), particularly its derivatives Norethisterone acetate and Norethisterone enanthate in sufficient doses induce oligozoospermia or azoospermia in males. Formulations further comprising an androgen, such as ... 06/29/06 - 20060142256 - Composition comprising a combination of an aromatase inhibitor, a progestin and an oestrogen and its use for the treatment of endometricosis The invention relates to a method of treating endometriosis using a combination of an aromatase inhibitor, a progestin and an oestrogen. The invention also relates to pharmaceutical formulations comprising said combination. ... 06/22/06 - 20060135496 - Methods of hormonal treatment utilizing ascending-dose extended cycle regimens The present invention provides ascending-dose extended cycle regimens in which a female is administered an estrogen and a progestin for a period of greater than 30 or 31 consecutive days, optionally followed by a hormone-free period or by a period of administration of estrogen. The disclosed regimens can be administered ... 06/15/06 - 20060128679 - Method for treatment of dysmenorrhea A method of treatment of dysmenorrhea in the context of oral contraception characterized by daily administration of ethinylestradiol and drospirenone in an extended regimen. ... 06/08/06 - 20060122158 - Pharmaceutical application of 15- or 16-substituted testosterone analogues The invention relates to pharmaceutical dosage units for oral, transmucosal or transdermal administration containing 15- or 16-substituted testosterone analogues, as well as to therapeutic methods that employ these testosterone analogues. More particularly, the invention is concerned with such pharmaceutical dosage units containing at least 10 μg of an androgenic steroid ... 05/18/06 - 20060106004 - Unique methods and formulations of bio-identical sex steroids for the treatment of pathophysiologic aberrations of menopause Consistent relief of physical and psychological disturbances in menopause is achieved by the administration of estrogenic hormones, which are bio-identical to natural estradiol and estriol, in a ratio ranging from 1.1:1.0 to 10.0:1.0, either with or without the combined administration of testosterone in a ratio of total estrogen to testosterone ... 05/11/06 - 20060100180 - Composition containing an androgenous 11b-halogen steroid and a progestational hormone, and male contraceptive based on said composition The invention relates to a novel chemical composition containing an androgenous 11β-halogen steroid and the progestational hormone of formula (I), to a pharmaceutical composition containing said chemical composition and to a male contraceptive based on said pharmaceutical composition. ... 05/04/06 - 20060094698 - Self-administered contraceptive injection of oily solution The subject invention provides a pharmaceutical formulation in the form of an oily solution for injection to a subject comprising a contraceptively and/or therapeutically effective amount of a long-acting progestogen and a contraceptively and/or therapeutically effective amount of a long-acting androgen dissolved in a pharmaceutically acceptable oily medium wherein the ... 04/27/06 - 20060089339 - Method of improving cumulative embryo score and quantity of fertilized ooytes, increasing euploidy rate and of normalizing ovarian function using an androgen such as dehydroepiandrosterone A method of improving cumulative embryo score may comprise administering an androgen to a human female, for example, DHEA, for at least about four consecutive months followed by harvesting and fertilizing oocytes and forming embryos. Between about 50 mg and about 100 mg of DHEA may be administered to a ... 04/27/06 - 20060089338 - Dosage form for hormonal contraception A dosage form for hormonal contraception containing a given number of hormone-containing daily units and a given number of hormone-free daily units for daily, oral administration, where the hormone-containing daily units each contain at most the minimum effective daily amount of folic acid for women and the hormone-free daily units ... 04/27/06 - 20060089337 - Estrogen replacement regimen The present invention provides an improved method to deliver estrogen to menopausal women comprising administering ultra-low dose estradiol alternating with standard-dose estradiol. ... 04/13/06 - 20060079491 - Method of female hormonal contraception using a fixed extended cycle hormonal preparation containing dienogest and ethinyl estradiol The fixed extended cycle method of female hormonal contraception includes continuous daily administration of daily dosage units of a monophasic preparation to a woman over a time period of n×21 days, wherein n=2, 3, 4 or 5, immediately followed by a seven-day pill-break in which the monophasic preparation is not ... 03/30/06 - 20060069071 - Treatment of dermatitis with dehydroepiandrosterone-glucocorticoid combinations Dermatitis can be effectively treated with the combined administration of dehydroepiandrosterone (DHEA) and a glucocorticoid. Systemic, topical and prepackaged DHEA-glucocorticoid embodiments are described. ... 03/16/06 - 20060058272 - Pharmaceutical composition for use as a contraceptive A pharmaceutical composition comprises, as a first active agent, 6β,7β;15β,16β-dimethylene-3-oxo-17α-pregn-4-ene-21,17-carbolactone (drospirenone) in an amount corresponding to a daily dosage, on administration of the composition, of from about 2 mg to about 4 mg, and, as a second active agent, 17α-ethinylestradiol (ethinylestradiol) in an amount corresponding to a daily dosage of ... 02/02/06 - 20060025390 - Treatment of hormone allergy and related symptoms and disorders The present disclosure provides methods and compositions for diagnosis and treatment of hormone allergy in a subject, including, without limitation, through measurement of elevated anti-hormone antibodies, e.g., IgE, IgG, and IgM. Target hormones may include estrogen and progesterone. Hormone allergy related symptoms and disorders may be treated by administration of ... 01/19/06 - 20060014728 - Hormone replacement therapy A method of hormone replacement therapy comprises administering to a woman in need of such therapy, estrogen in an hormone replacement therapy effective amount and antiprogestin in an amount which is effective both to inhibit estrogen-induced endometrial proliferation and to effect a state of substantial amenorrhea, in the absence of ... 01/12/06 - 20060009428 - Cyclic progestin regimens and kits A method of contraception is provided which involves delivery of 21 to 27 consecutive days of a progestin in the absence of an estrogen or other steroidal compound, followed by 1 to 7 days without an effective amount of an active agent. Also described is a pharmaceutically useful kit to ... 12/29/05 - 20050288264 - Dosage regimen and pharmaceutical composition for emergency contraception The invention relates to a dosage regimen for emergency contraception, to pharmaceutical compositions of the same purpose, to the use of levenorgestrel for the manufacture of pharmaceutical compositions for the same purpose, as well as to the manufacturing process of these pharmaceutical compositions. According to the invention the emergency ... 12/22/05 - 20050282790 - Therapeutic gestagens for the treatment of premenstrual dysphoric disorder This invention describes the use of a therapeutic gestagen (e.g., drospirenone, cyproterone acetate, dienogest) for the production of a pharmaceutical agent for the treatment of premenstrual dysphoric disorder (PMDD), optionally in combination with a natural or synthetic estrogen (e.g., estradiol or ethinylestradiol). ... 12/08/05 - 20050272712 - Compositions and methods for treatment of premenstrual dysphoric disorder The present invention relates to a method for treating premenstrual dysphoric disorder through administration of at least one progestin and at least one estrogen to a female subject. ... 12/01/05 - 20050267084 - Hormonal contraceptive containing a combination of ethinyloestradiol and chlormadinone acetate The present invention relates to a hormonal contraceptive including 21 to 25 hormone-containing daily units, which contain a combination of ethinyloestradiol in an amount of ≧25 μg and chlormadinone acetate in an amount of ≧5 mg, and optionally 7 to 3 hormone-free daily units for oral administration to women. ... 12/01/05 - 20050267083 - Dosage form for hormonal contraception The present invention relates to a dosage form for hormonal contraception containing a given number of hormone-containing daily units and a given number of hormone-free daily units for daily, oral administration, characterised in that the hormone-containing daily units each contain at most the minimum effective daily amount of folic acid ... 12/01/05 - 20050267082 - Hormonal contraceptive containing a combination of ethinyloestradiol and chlormadinone acetate The present invention relates to a hormonal contraceptive including at least 120 hormone-containing daily units, which contain 5 to 50 μg of ethinyloestradiol and 1 to 5 mg of chlormadinone acetate, and optionally 7 to 3 hormone-free daily units for uninterrupted oral administration to women. ... 12/01/05 - 20050267081 - Use of a combination of ethinyloestradiol and chlormadinone acetate to produce a pharmaceutical preparation The invention relates to the use of a combination of ethinyloestradiol and chlormadinone acetate to produce a pharmaceutical preparation for the treatment of androgen-induced disorders and for hormone replacement therapy and for the treatment of dysmenorrhoea and for stabilising the menstrual cycle and for the treatment of menstrual cycle-dependent complaints ... 11/10/05 - 20050250747 - Management of breakthrough bleeding in extended hormonal contraceptive regimens The present invention relates to a flexible extended use regimen for a hormonal contraceptive useful to manage bleeding problems associated with fixed extended use of hormonal contraceptives and to a pharmaceutical package containing the respective hormonal contraceptive. ... 11/10/05 - 20050250746 - Premenstrual dysphoric disorder medication A medication to treat the symptoms of premenstrual syndrome and similar conditions related to the periodic change in the physiological level of hormones in a woman's body. ... 11/03/05 - 20050245492 - Use of equol for treating skin diseases Equol (7-hydroxy-3(4′hydroxyphenyl)-chroman), the major metabolite of the phytoestrogen daidzein, specifically binds and blocks the hormonal action of 5α-dihydrotestosterone (DHT) in vitro and in vivo. Equol can bind circulating free DHT and sequester it from the androgen receptor, thus altering growth and physiological hormone responses that are regulated by androgens. These ... 10/27/05 - 20050239758 - Hormone treatment of multiple sclerosis Compositions and/or methods are provided for treating multiple sclerosis and/or an autoimmune condition comprising administering to a human an effective amount of a hormone dilution. ... 10/27/05 - 20050239757 - Hormone treatment of macular degeneration Compositions and/or methods are provided for treating macular degeneration and/or a degenerative ocular condition comprising administering to a human an effective amount of a hormone dilution. ... 10/13/05 - 20050227952 - Extended cycle multiphasic oral contraceptive method A multiphasic method of contraception that provides for sequentially administering to a female of child bearing age: (a) a Phase I composition containing a progestogen in an amount equivalent to about 0.5 to about 1.5 mg norethindrone acetate and an estrogen in an amount equivalent to about 5 to about ... 10/06/05 - 20050222099 - Pregnane steroids for use in the treatment of cns disorders Steroid compounds prossessing a hydrogen donor in 3beta position, either in the form of a hydroxy- or a sulfate group, function as efficient blockers of the 3alpha-hydroxy-pregnan-steroid action and thus have utility as therapeutic substances for the prevention and/or treatment of steroid related CNS disorders. Treatment methods based on the ... 09/29/05 - 20050215536 - Sequential sprm/ progestin treatment The methods provided herein comprise administering a selective progesterone receptor modulator (SPRM) during a first dosing period and at least one progestogen during a second dosing period. The dosing periods can run concomitantly or sequentially with or without a period where neither the SPRM nor the progestogen is administered. ... 09/29/05 - 20050215535 - Sequential sprm/progestin treatment The methods provided herein comprise administering a selective progesterone receptor modulator (SPRM) during a first dosing period and at least one progestogen during a second dosing period. The dosing periods can run concomitantly or sequentially with or without a period where neither the SPRM nor the progestogen is administered. ... 08/04/05 - 20050171071 - Menstrual cycle control and improvement of conception rates in females The present invention relates to methods of increasing likelihood of conception, treatment of low fecundity and/or providing menstrual cycle control without suppressing ovulation in a female comprising administering an effective dose of at least one estrogen and at least one progestin within a treatment period of at least 21 days ... 07/14/05 - 20050153946 - Temperature-stable formulations, and methods of development thereof One embodiment of the present invention relates to a method of preparing a concentrated pharmaceutical formulation, comprising the steps of: combining in a container a therapeutic agent, a solvent and at least one pharmaceutically acceptable excipient to give a solution; adding to said solution a seed crystal of said compound ... 07/07/05 - 20050148560 - Prevention and treatment of hypertensive heart diseases by the selective estrogens 8beta-vinyl-estra-1,3,5(10)-trien-3,17beta-diol and 17beta-fluor-9alpha-vinyl-estra-1,3,5(10)-trien-3,16alpha-diol The present invention relates to the use of the ERβ agonists 8β-Vinyl-estra-1,3,5(10)-trien-3,17β-diol and 17β-Fluor-9α-vinyl-estra-1,3,5(10)-trien-3,16α-diol for production of medicaments for the prevention and/or treatment of hypertensive heart disease, especially for the prevention and/or treatment of one or more of the conditions selected from the group of (1) hypertension, (2) cardiac hypertrophy ... 07/07/05 - 20050148559 - Method of preventing or treating benign gynaecological disorders The present invention relates to a method of preventing or treating benign estrogen sensitive gynaecological disorders in a female mammal, wherein the method comprises the administration to said female mammal of a combination of progestogen and androgen in an amount that is therapeutically effective to prevent or reduce the symptoms ... 06/30/05 - 20050143359 - Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration The present invention provides contraceptive regimens in which a female is administered a combined dosage form of estrogen and progestin followed by a period of administration of estrogen. The disclosed contraceptive regimens can be administered to a female as a method of providing non-contraceptive benefits. ... 06/16/05 - 20050130944 - Method of making and using 7alpha,11beta-dimethyl-17beta-hydroxyestr-4-en-3-one 17-undecanoate for various hormonal therapies, dosage forms comprising 7α,11β-dimethyl-17β-hydroxyestr-4-en-3-one 17-undecanoate, and processes for its preparation. ... ### FreshPatents.com Support |